SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-224404
Filing Date
2021-07-26
Accepted
2021-07-26 16:54:57
Documents
16
Period of Report
2021-07-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d146391d8k.htm   iXBRL 8-K 40675
2 EX-2.1 d146391dex21.htm EX-2.1 31607
3 EX-2.2 d146391dex22.htm EX-2.2 13716
4 EX-99.1 d146391dex991.htm EX-99.1 28550
8 GRAPHIC g146391g0726174011226.jpg GRAPHIC 3342
  Complete submission text file 0001193125-21-224404.txt   271792

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA sbbp-20210723.xsd EX-101.SCH 2901
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE sbbp-20210723_lab.xml EX-101.LAB 18139
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sbbp-20210723_pre.xml EX-101.PRE 11414
9 EXTRACTED XBRL INSTANCE DOCUMENT d146391d8k_htm.xml XML 3361
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

IRS No.: 981130690 | State of Incorp.: L2
Type: 8-K | Act: 34 | File No.: 001-37569 | Film No.: 211114743
SIC: 2834 Pharmaceutical Preparations